<DOC>
	<DOCNO>NCT00559312</DOCNO>
	<brief_summary>Even patient milder COPD significant physiological abnormality become pronounced exercise , lead intolerable breathe discomfort ( dyspnea ) . While compel physiological rationale efficacy inhale corticosteroid/long-acting bronchodilator combination therapy [ i.e. , fluticasone 250μg/salmeterol 50μg ( FSC250/50 ) ] moderate severe COPD , little information available potential impact therapy milder symptomatic disease . This study first explore mechanisms dyspnea activity limitation milder COPD determine sound physiological rationale use FSC therapy subpopulation .</brief_summary>
	<brief_title>The Effect Fluticasone/Salmeterol Combination Exertional Breathlessness Patients With Mild COPD</brief_title>
	<detailed_description />
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Stable mild COPD , FEV1/FVC &lt; 0.7 FEV1 &gt; 60 % predict , Activityrelated dyspnea ( i.e. , Baseline Dyspnea Index focal score &lt; 9 , MRC dyspnea scale &gt; 2 ) , Cigarette smoke history ≥20 packyears . Presence significant disease COPD could contribute dyspnea exercise limitation , Important contraindication clinical exercise testing , Use daytime oxygen , History Asthma .</criteria>
	<gender>All</gender>
	<minimum_age>41 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>mild COPD</keyword>
	<keyword>dyspnea</keyword>
	<keyword>exercise</keyword>
	<keyword>combination therapy</keyword>
</DOC>